Early Phase 1
N=35
Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model
Gingivitis
Bottom Line
View on ClinicalTrials.gov: NCT00779909 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Oct 2017
Primary outcome: Primary: Proportion of Sites That Bleed on Probing
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- vitamin D3 (Drug); Placebo (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Boston University
- Primary completion
- May 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Sites That Bleed on Probing |
— | — |
| PRIMARY Mandibular Modified Gingival Index (MGI) Score |
1.83; 1.76; 1.62; 1.67; 2.12; 1.97 | — |
| PRIMARY Maxillary Modified Gingival Index (MGI) Score |
1.78; 1.63; 1.57; 1.61; 2.11; 1.87 | — |
| SECONDARY Mandibular Plaque Index (PI) Score |
1.84; 1.77; 1.82; 1.82; 2.92; 2.93 | — |
| SECONDARY Maxillary Plaque Index (PI) Score |
1.56; 1.71; 1.69; 1.68; 2.77; 3 | — |
| SECONDARY Gingival Crevicular Fluid (GCF) Volume |
38.1; 49.1; 37.1; 57.6; 50.8; 66.5 | — |
| SECONDARY Gingival Crevicular Fluid (GCF) Concentrations of TNF-alpha, IL1-beta, IL-2, IL-12 |
0.97; 1.53; 1.34; 1.87; 1.00; 1.11 | — |
| SECONDARY Serum Calcium |
9.6; 9.1; 9.2; 9.1; 9.4; 9.2 | — |
| SECONDARY Urinary Calcium/Creatinine Ratio |
0.07; 0.06; 0.07; 0.09; 0.09; 0.07 | — |
Summary
The burden of chronic gingivitis and periodontitis in the US is disproportionately high among Non-Hispanic Blacks compared to Non-Hispanic Whites. Chronic gingivitis is a highly prevalent chronic inflammatory disease that may progress into periodontitis, a major cause of tooth loss, Data from in-vitro and animal studies suggest anti-inflammatory effects of vitamin D; however, if and over what dose-range vitamin D may have anti-inflammatory effects in humans is uncertain. Recent clinical studies indicate that beneficial effects of vitamin D for several important outcomes may occur over a wide range of serum 25-hydroxyvitamin D (25-OHD) concentrations, possibly up to concentrations that would require vitamin D intakes ranging from 2 to more than 10 ten times higher than the current RDA for vitamin D. Because dark skin pigmentation is a potent inhibitor of vitamin D photosynthesis, Non-Hispanic Blacks have much lower 25-OHD serum levels than Non-Hispanic Whites. These differences in vitamin D status may partially explain the racial disparities in prevalence of chronic gingivitis and periodontitis observed in the US.
We hypothesize that oral cholecalciferol supplementation can reduce susceptibility to gingivitis over a wide range of serum 25-OHD concentrations in Non-Hispanic Whites and Non-Hispanic Blacks. We propose to conduct a simple, single-center, randomized, double-blind, placebo-controlled parallel-group dose-ranging study. We will compare placebo to doses of 500 IU, 2,500 IU and 5,000 IU vitamin D3 per day. We will compare the severity of gingival inflammation that develops in response to a 28-day period of unlimited plaque growth (experimental gingivitis) between dosage groups. Furthermore, we will evaluate the association between achieved 25-OHD levels and gingival inflammation.
The results of this study will have several important implications, as dietary vitamin D supplementation may be a simple, safe and inexpensive means by which to reduce racial/ethnic disparities in gingivitis, as well as to reduce the overall burden of oral disease in the population as a whole. The study will elucidate the dose-response relationship of the anti-inflammatory effects of vitamin D, which in turn may lead to a revision of the current recommendations regarding nutritional supplementation of vitamin D in order to optimize the prevention of important medical conditions and diseases and reduce racial health disparities.
Eligibility Criteria
Inclusion Criteria
- informed written consent
- healthy subjects age 18-64 years old
- serum 25-hydroxyvitamin D concentration 3
- Current smoking or former smoking with cessation ULN),
- hypocalcemia (serum calcium ULN),
- hypoparathyroidism (serum PTH concentration < LLN)
- any cardiac rhythm abnormalities on baseline ECG
- use of tanning beds/unwillingness to abstain from use of tanning beds during study
- planned travel during study period / unwillingness to abstain from travel to the South or High Altitudes
- unwillingness to abstain from use of any supplements (including vitamin/mineral and herbal supplements) during study period
Data sourced from ClinicalTrials.gov (NCT00779909). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.